THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.1] ID: TIP-MED-000233

Tamsulosin Hydrochloride (and Silodosin / Alfuzosin comparison)

Active Ingredient / Scientific Identity: Tamsulosin Hydrochloride • Class: Uroselective Alpha-1A and Alpha-1D Adrenoceptor Antagonist (Relaxes Prostatic Smooth Muscle & Bladder Neck to Improve Urinary Flow)

⚖️ Compare Profile
Generic / Entity NameTamsulosin Hydrochloride (and Silodosin / Alfuzosin comparison) ([12.1])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassUroselective Alpha-1A and Alpha-1D Adrenoceptor Antagonist (Relaxes Prostatic Smooth Muscl
Available Dosage FormsModified-Release (MR) Capsules / Tablets: 0.4 mg (400 mcg) (also 0.2 mg in select brands)
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Excreted <10% unchanged in urine—no dose adjustment required in mild-to-severe CKD (down to CrCl 10 mL/min). Hepatic:
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Tamsulosin Hydrochloride (and Silodosin / Alfuzosin comparison) (TIP-MED-000233, Reference Code [12.1]) is classified under Urological & Renal Stone Medicines (Ch 12) as a Uroselective Alpha-1A and Alpha-1D Adrenoceptor Antagonist (Relaxes Prostatic Smooth Muscle & Bladder Neck to Improve Urinary Flow). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.1], p. 155): Urimax (Cipla), Veltam (Intas), Contiflo-OD (Sun Pharma), Dynapres; In FDC with Dutasteride: Urimax-D, Veltam-Plus; With Finasteride: Urimax-F. (Related uroselective alpha-1A blocker: Silodosin 4 mg/8 mg [Silodal, Rapilif]) — Strengths & Dosage Forms: Modified-Release (MR) Capsules / Tablets: 0.4 mg (400 mcg) (also 0.2 mg in select brands)
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.1], p. 155): Urimax (Cipla), Veltam (Intas), Contiflo-OD (Sun Pharma), Dynapres; In FDC with Dutasteride: Urimax-D, Veltam-Plus; With Finasteride: Urimax-F. (Related uroselective alpha-1A blocker: Silodosin 4 mg/8 mg [Silodal, Rapilif]) — Strengths & Dosage Forms: Modified-Release (MR) Capsules / Tablets: 0.4 mg (400 mcg) (also 0.2 mg in select brands)
Dosage Forms & Available Strengths:
Modified-Release (MR) Capsules / Tablets: 0.4 mg (400 mcg) (also 0.2 mg in select brands)
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Uroselective Alpha-1A and Alpha-1D Adrenoceptor Antagonist (Relaxes Prostatic Smooth Muscle & Bladder Neck to Improve Urinary Flow) acting on target receptor/enzyme pathways in Urological & Renal Stone Medicines (Ch 12): clinical efficacy is mediated via Uroselective Alpha-1A and Alpha-1D Adrenoceptor Antagonist (Relaxes Prostatic Smooth Muscle & Bladder Neck to Improve Urinary Flow) for Functional lower urinary tract symptoms (LUTS: urinary hesitancy, weak stream, incomplete emptying, nocturia) associated with Benign Prostatic Hyperplasia (BPH); medical expulsive therapy (MET) to facilitate spontaneous passage of distal ureteric calculi (<8–10 mm kidney stones)..

4. Therapeutic Indications & Evidence-Supported Uses

  • Functional lower urinary tract symptoms (LUTS: urinary hesitancy, weak stream, incomplete emptying, nocturia) associated with Benign Prostatic Hyperplasia (BPH)
  • medical expulsive therapy (MET) to facilitate spontaneous passage of distal ureteric calculi (<8–10 mm kidney stones)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: 0.4 mg (1 capsule/tablet) once daily (taken 30 minutes after the same meal each day; usually dinner). Follow urologist/physician prescription.

Administration & Meal Timing: MUST be taken 30 minutes AFTER the same meal every day (typically 30 minutes after Dinner)! NEVER take on an empty stomach! (Taking tamsulosin on an empty stomach increases oral bioavailability by 30% and increases peak plasma concentration [Cmax] by 40% to 70%, causing precipitous postural hypotension, dizziness, and fainting!). Swallow MR capsule/tablet whole—do NOT crush, chew, or open! | Once daily in the evening (30 minutes after dinner / before bedtime).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Excreted <10% unchanged in urine—no dose adjustment required in mild-to-severe CKD (down to CrCl 10 mL/min). Hepatic: Avoid in severe hepatic impairment (Child-Pugh C).
Elimination & Renal Adjustment:
Renal: Excreted <10% unchanged in urine—no dose adjustment required in mild-to-severe CKD (down to CrCl 10 mL/min). Hepatic: Avoid in severe hepatic impairment (Child-Pugh C).
Hepatic Impairment Considerations:
Renal: Excreted <10% unchanged in urine—no dose adjustment required in mild-to-severe CKD (down to CrCl 10 mL/min). Hepatic: Avoid in severe hepatic impairment (Child-Pugh C).

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • 1. MANDATORY CATARACT SURGERY WARNING — INTRAOPERATIVE FLOPPY IRIS SYNDROME (IFIS)! Tamsulosin (and Silodosin/Alfuzosin) binds avidly and semi-permanently to Alpha-1A receptors in the iris dilator muscle! During phacoemulsification cataract surgery, this causes a triad of billowing floppy iris, progressive intraoperative pupil constriction, and iris prolapse through surgical incisions—risking posterior capsule rupture and vision loss! Even if stopped weeks or months before cataract surgery, IFIS can still occur—the ophthalmic surgeon MUST be informed in advance so iris hooks/phenylephrine can be prepared, and starting tamsulosin newly in a patient awaiting imminent cataract surgery should be deferred until after surgery! 2. Contraindicated in history of orthostatic syncope and severe hepatic failure.

Key Clinical Precautions: Renal: Excreted <10% unchanged in urine—no dose adjustment required in mild-to-severe CKD (down to CrCl 10 mL/min). Hepatic: Avoid in severe hepatic impairment (Child-Pugh C).

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Orthostatic dizziness / postural lightheadedness (especially after the first dose or upon standing up at night to urinate!), abnormal ejaculation / retrograde ejaculation into the bladder (8–18% with Tamsulosin; >28% with Silodosin—harmless but alarming if unwarned!), nasal congestion/rhinitis (nasal turbinate alpha-1 vasodilation), headache.
  • First-Dose Orthostatic Syncope and Hip-Fracture Falls, Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery, priapism (extremely rare), Stevens-Johnson syndrome (rare).
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • PDE-5 Inhibitors (Sildenafil, Tadalafil, Vardenafil) & Other Alpha-Blockers (Prazosin, Terazosin, Carvedilol): Profound additive vasodilation and symptomatic hypotension! (Never combine two alpha-blockers, and space PDE-5 inhibitors by ≥4–6 hours)
  • Potent CYP3A4 & CYP2D6 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin, Paroxetine, Fluoxetine, Terbinafine, Cimetidine): Increase tamsulosin plasma exposure 2- to 3-fold (causing severe postural syncope!)
  • Antihypertensives & Loop Diuretics: Additive postural blood pressure drop

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: 3 Non-Negotiable Counter Warnings for Urimax / Veltam: 1. The '30 Minutes After Dinner & Sit Before Standing' Rule: Always swallow the capsule whole 30 minutes after dinner. When waking up at night to pass urine (especially during the first week), sit on the edge of the bed for 60 seconds and dangle your legs before standing up so you do not faint on the bathroom floor! 2. Cataract Surgery Alert: Ask every elderly patient: 'Are you planning Motiyabind (cataract) eye surgery in the coming months?' Tell them they MUST inform their eye surgeon that they take Urimax/Veltam! 3. Reassure that stuffy nose or reduced semen volume during ejaculation is a benign muscle-relaxing effect.
  • Meal & Clock Timing Instruction: MUST be taken 30 minutes AFTER the same meal every day (typically 30 minutes after Dinner)! NEVER take on an empty stomach! (Taking tamsulosin on an empty stomach increases oral bioavailability by 30% and increases peak plasma concentration [Cmax] by 40% to 70%, causing precipitous postural hypotension, dizziness, and fainting!). Swallow MR capsule/tablet whole—do NOT crush, chew, or open! (Once daily in the evening (30 minutes after dinner / before bedtime).)
  • Missed Dose Protocol: Take 30 minutes after the next meal on the same day; if missed for several consecutive days, restart 30 minutes after dinner with bedtime postural precautions.
  • Geriatric Dispensing Pearl: While tamsulosin is much more uroselective than older non-selective alpha-blockers (Prazosin [Prazopress] or Terazosin [Hytrin], which are flagged in Beers Criteria), night-time bathroom falls remain a major hazard when elderly men combine Tamsulosin with antihypertensives or diuretics.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Modified-Release (MR) Capsules / Tablets: 0.4 mg (400 mcg) (also 0.2 mg in select brands)

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.1] (p. 155)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.